Violin Jonathan 4

What Happened
Jonathan Violin, a director of Dianthus Therapeutics (DNTH), received a derivative award on 2026-05-21 covering 6,090 shares. The transaction is reported as an award/grant (code A) with a reported transaction price of $0.00 (no cash paid at grant). This is a time‑vesting equity award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-21; Form 4 filed 2026-05-22 (timely filing).
• Instrument: Derivative stock award (stock option award underlying 6,090 shares).
• Shares/amount: 6,090 shares reported as acquired; transaction price shown as $0.00.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote (vesting): The shares underlying the stock option award vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. (Footnote F1)
• No indication of a 10b5-1 plan, tax withholding, cashless exercise, or late filing in the provided data.

Context
This report documents a standard director equity grant intended for retention/incentive. Because it’s a derivative award with vesting conditions and no immediate sale, it does not represent an immediate cash/market transaction. As always, such grants are routine for compensation and do not by themselves indicate the insider’s view on the company’s stock price.